세계의 병리학 분야 인공지능(AI) 시장 : 컴포넌트별, 기술 유형별, 병리 유형별, 질환 유형별, 전개 모델별, 용도별, 최종사용자별 - 예측(2025-2030년)

The Artificial Intelligence in Pathology Market was valued at USD 101.58 million in 2024 and is projected to grow to USD 116.52 million in 2025, with a CAGR of 14.86%, reaching USD 233.36 million by 2030.

Artificial Intelligence has rapidly transitioned from a futuristic concept into a transformative force within the pathology domain. The intersection of advanced algorithms, expansive datasets, and robust computing power has paved the way for remarkable breakthroughs, reshaping how pathological analysis and diagnostics are conducted. This convergence of technology and healthcare is not only enhancing the accuracy and speed of disease detection but also opening new avenues for innovation and research. The current climate is ripe with opportunities as cutting-edge solutions improve workflow efficiency, elevate diagnostic precision, and streamline the integration of data across diverse clinical settings. As the field accelerates towards a more digitized future, stakeholders must embrace these technological advances, which continue to drive improvements in patient care and operational outcomes.

In recent decades, technology has continuously disrupted traditional methods within pathology. As digital solutions become more sophisticated, there is an increasing reliance on data-driven decisions, augmented imaging, and machine-assisted diagnostics. This wave of transformation is clear evidence of the critical role that artificial intelligence is playing in redefining operational standards. From academic research to large-scale clinical implementations, the impact of AI is visible at every step of the diagnostic process, gradually turning the tide towards more integrated and intuitive systems that promise to deliver better clinical outcomes and streamlined workflows.

Transformative Shifts in the Pathology Landscape

The landscape of pathology is undergoing significant transformation, driven predominantly by the integration of artificial intelligence technologies. Traditional methods that often relied on manual analyses are rapidly being supplanted by more innovative and data-centric approaches. This evolution is underpinned by continuous advancements in machine learning, computer vision, and deep neural networks which have collectively improved the speed and reliability of diagnostic procedures.

These technological shifts are not confined to improvements in image analysis or pattern recognition alone; they are laying the foundation for a complete overhaul of operational dynamics. The evolution from standard pathology practices to digitally enhanced workflows presents opportunities to streamline processes and optimize resource allocation. Decision-making is evolving from solely human judgment to a symbiosis of human expertise enhanced by computational support. Such convergence is fostering an environment where diagnostic precision is enhanced, operational costs are reduced, and the overall patient care continuum is being reimagined.

In addition, real-time data processing and integration are further accelerating this digital transformation. Institutions are now leveraging vast amounts of data, a trend that is being bolstered by cloud technologies and scalable computing power. These factors collectively usher in a new era where pathology not only becomes more efficient but also more accessible globally, paving the way for further breakthroughs in clinical diagnostics and personalized medicine.

Key Segmentation Insights in the AI Pathology Market

The segmentation analysis of the AI pathology market reveals diverse dimensions that paint a comprehensive picture of its growth trajectory and areas of opportunity. The market analysis based on component distinguishes between the services and software aspects, with services further examined through consultation, installation and integration, as well as support and maintenance. On the software side, segmentation delves into distinct categories including clinical trial and research software, data management software, diagnostic software, and image analysis software. Each category provides nuanced insights into how specific technological applications are configured to support the evolving needs of pathology laboratories and research institutions.

Furthermore, when considering the market through the lens of technology type, it is studied across areas such as big data analytics, computer vision, deep learning, machine learning, and natural language processing. This focus on technology emphasizes the breadth of innovation driving advancements, transcending traditional methodologies through integration of sophisticated analytical techniques. Analysis based on pathology type further segments the market into anatomic pathology, clinical pathology, and molecular pathology, thereby addressing the wide range of diagnostic practices and technologies in clinical use today.

Also, the market is segmented based on disease type, focusing on areas such as cancer, cardiovascular diseases, and neurodegenerative disorders. This segmentation not only highlights the areas of highest clinical demand but also reflects the specialized nature of AI applications in identifying and diagnosing complex conditions. Complementing the disease-type segmentation, the deployment model offers a clear differentiation between cloud-based and on-premise solutions, each presenting its own set of advantages and limitations based on the scale and security requirements of the pathology units involved.

In addition, application-based segmentation encompasses a spectrum from clinical trials and research to digital pathology and image analysis, disease diagnosis and detection, drug discovery and development, along with prognostics and risk assessment. This holistic understanding of applications underscores the role of AI in reading, interpreting, and communicating essential clinical data. Lastly, examining the market based on the end user reveals a diverse clientele that includes biotechnology companies, contract research organizations, hospitals and clinics, pharmaceutical companies, and research institutions. Such diverse segmentation reflects the increasingly interconnected nature of technology innovation within the pathology sector and its potential to serve a varied clientele across the healthcare continuum.

Based on Component, market is studied across Services and Software. The Services is further studied across Consultation, Installation & Integration, and Support & Maintenance. The Software is further studied across Clinical Trial and Research Software, Data Management Software, Diagnostic Software, and Image Analysis Software.

Based on Technology Type, market is studied across Big Data Analytics, Computer Vision, Deep Learning, Machine Learning, and Natural Language Processing.

Based on Pathology Type, market is studied across Anatomic Pathology, Clinical Pathology, and Molecular Pathology.

Based on Disease Type, market is studied across Cancer, Cardiovascular Diseases, and Neurodegenerative Disorders.

Based on Deployment Model, market is studied across Cloud-Based and On-Premise.

Based on Application, market is studied across Clinical Trials & Research, Digital Pathology & Image Analysis, Disease Diagnosis & Detection, Drug Discovery & Development, and Prognostics & Risk Assessment.

Based on End User, market is studied across Biotechnology Companies, Contract Research Organization, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutions.

Regional Dynamics Shaping Market Growth

The regional analysis of the AI pathology market showcases distinct yet interconnected trends across different geographies. The market dynamics in the Americas highlight a robust foundation with extensive research collaborations and progressive regulatory frameworks that foster rapid technological adoption. In another part of the globe, the region encompassing Europe, the Middle East, and Africa presents a unique blend of mature healthcare systems and emerging digital economies, all of which catalyze the integration of AI solutions into traditional pathology practices. Asia-Pacific, too, offers a competitive landscape driven by innovative technology adoption and expansive healthcare reforms, positioning it as a pivotal player in the global arena.

Each region contributes uniquely to the overall market narrative by emphasizing different aspects of technology adoption, integration, and innovation. While the Americas set high benchmarks in terms of research investments and clinical implementations, Europe, the Middle East, and Africa emphasize balancing advanced digital solutions with localized healthcare needs. Asia-Pacific stands out for its rapid urbanization and increasing tech-savvy populations, driving significant investment inflows that are critical to supporting cutting-edge developments in the field. Together, these regional insights not only underscore the heterogeneous nature of market evolution but also serve as vital indicators of where future growth and innovation are likely to concentrate.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Leading Companies in AI Pathology

The competitive landscape in the AI pathology market features an array of formidable players demonstrating robust capabilities and innovative solutions across the spectrum of diagnostic technologies. Companies such as aetherAI and Aiforia Technologies Oyj are at the forefront, harnessing advanced algorithms and state-of-the-art imaging solutions to transform data into actionable insights. Akoya Biosciences, Inc. has established a strong presence by deploying sophisticated platforms that enable precise quantification of biomarkers, while Deep Bio, Inc. continues to push boundaries with novel approaches in digital diagnostics. Evident Corporation and F. Hoffmann-La Roche Ltd. offer extensive portfolios that combine both high-performance hardware and intuitive software solutions.

Further, organizations like Ibex Medical Analytics Ltd. and Indica Labs, Inc. are revolutionizing diagnostic procedures through the incorporation of machine learning and real-time analytics. Innovators such as Inspirata, Inc., LUMEA, Inc., and MindPeak GmbH are redefining research paradigms by seamlessly integrating AI into clinical workflows. The landscape is further enriched by the contributions of Nucleai Inc. and OptraSCAN Inc., whose methodologies intersect advanced image processing with diagnostic precision. Paige.AI, Inc. and PathAI, Inc. are recognized for their deep learning platforms that significantly enhance diagnostic accuracy and workflow speed. Leaders like Proscia Inc. and Techcyte, Inc. are implementing systems designed to scale across global pathology networks, while Tempus Labs, Inc., Tribun Health, Visikol, Inc. by CELLINK, and Visiopharm A/S are pioneering collaborative efforts that blend clinical expertise with technological innovation. Collectively, these companies are not only setting benchmarks for technological performance but are also instrumental in driving the evolution of AI-powered diagnostic applications globally.

The report delves into recent significant developments in the Artificial Intelligence in Pathology Market, highlighting leading vendors and their innovative profiles. These include aetherAI, Aiforia Technologies Oyj, Akoya Biosciences, Inc., Deep Bio, Inc., Evident Corporation, F. Hoffmann-La Roche Ltd., Ibex Medical Analytics Ltd., Indica Labs, Inc., Inspirata, Inc., LUMEA, Inc., MindPeak GmbH, Nucleai Inc., OptraSCAN Inc., Paige.AI, Inc., PathAI, Inc., Proscia Inc., Techcyte, Inc., Tempus Labs, Inc., Tribun Health, Visikol, Inc. by CELLINK, and Visiopharm A/S. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to develop a strategic roadmap that leverages the transformative potential of AI technologies within the pathology domain. It is imperative to engage in detailed market analysis to tailor solutions that address specific operational challenges and patient care needs. Decision-makers should prioritize investments in scalable digital platforms while ensuring that robust data governance frameworks are in place to support patient confidentiality and regulatory compliance.

It is advisable to foster partnerships with technology innovators and academic institutions to co-develop solutions that ensure integration of the latest AI methodologies. By aligning research initiatives with practical implementations, leaders can ensure ongoing innovation that adapts to emerging trends in predictive analytics and precision diagnostics. Additionally, optimizing workforce training programs to enhance digital proficiency will be critical, aligning human resources with technology-driven requirements. The ongoing emphasis on cloud-based and on-premise solutions points to the need for flexible deployment models that can meet the varying demands of large institutions as well as smaller healthcare providers.

Leaders should also invest in integrated diagnostic systems designed to work seamlessly with existing hardware infrastructures, thereby minimizing transitional hurdles and maximizing return on investment. Continuous monitoring of key performance indicators is essential to assess the effectiveness of implemented solutions and drive iterative enhancements. In this manner, fostering an environment that not only embraces change but also anticipates future disruptions will be paramount in staying ahead in a competitive market landscape.

Conclusion and Future Outlook

In conclusion, the advent of artificial intelligence in pathology represents a paradigm shift that is set to redefine the industry landscape. Innovations in deep learning, data analytics, and computer vision are not merely incremental improvements but are foundational changes that enhance the accuracy and efficiency of diagnostic practices. As the market continues to mature, the integration of AI is poised to revolutionize the clinical process, driving significant improvements in workflow integration, predictive accuracy, and patient outcomes.

The future promises continued evolution, where artificial intelligence will drive not only diagnostic innovations but also catalyze a broader transformation within healthcare systems. From strategic investments in digital platforms to collaborations that bridge technology and clinical expertise, the interplay of innovative technology and robust regulatory practices will set the stage for sustained growth. As the industry adapts to this new wave of digital disruption, leaders must remain agile, continuously evolving their strategies to harness the full potential of AI-driven solutions. By doing so, they will ensure that the promise of artificial intelligence translates into real-world benefits both for practitioners and patients alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of AI-powered diagnostic tools by healthcare providers
    • 5.1.1.2. Rising interest in AI-driven tumor profiling to personalize cancer treatment
    • 5.1.1.3. Surging need for AI in automating routine lab processes
  • 5.1.2. Restraints
    • 5.1.2.1. High initial investment costs and interoperability issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Partnerships and collaborations to advance AI Integration in pathology laboratories
    • 5.1.3.2. Investments and funding to enhance precision medicine with AI
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and compliance issues associated with AI deployment in the pathology sector
• 5.2. Market Segmentation Analysis
  • 5.2.1. Component: Increasing usage of data management software for enhancing AI applications in pathology
  • 5.2.2. End User: Adoption of artificial intelligence in pathology for hospitals & clinics in revolutionizing patient care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Intelligence in Pathology Market, by Component

• 6.1. Introduction
• 6.2. Services
  • 6.2.1. Consultation
  • 6.2.2. Installation & Integration
  • 6.2.3. Support & Maintenance
• 6.3. Software
  • 6.3.1. Clinical Trial and Research Software
  • 6.3.2. Data Management Software
  • 6.3.3. Diagnostic Software
  • 6.3.4. Image Analysis Software

7. Artificial Intelligence in Pathology Market, by Technology Type

• 7.1. Introduction
• 7.2. Big Data Analytics
• 7.3. Computer Vision
• 7.4. Deep Learning
• 7.5. Machine Learning
• 7.6. Natural Language Processing

8. Artificial Intelligence in Pathology Market, by Pathology Type

• 8.1. Introduction
• 8.2. Anatomic Pathology
• 8.3. Clinical Pathology
• 8.4. Molecular Pathology

9. Artificial Intelligence in Pathology Market, by Disease Type

• 9.1. Introduction
• 9.2. Cancer
• 9.3. Cardiovascular Diseases
• 9.4. Neurodegenerative Disorders

10. Artificial Intelligence in Pathology Market, by Deployment Model

• 10.1. Introduction
• 10.2. Cloud-Based
• 10.3. On-Premise

11. Artificial Intelligence in Pathology Market, by Application

• 11.1. Introduction
• 11.2. Clinical Trials & Research
• 11.3. Digital Pathology & Image Analysis
• 11.4. Disease Diagnosis & Detection
• 11.5. Drug Discovery & Development
• 11.6. Prognostics & Risk Assessment

12. Artificial Intelligence in Pathology Market, by End User

• 12.1. Introduction
• 12.2. Biotechnology Companies
• 12.3. Contract Research Organization
• 12.4. Hospitals & Clinics
• 12.5. Pharmaceutical Companies
• 12.6. Research Institutions

13. Americas Artificial Intelligence in Pathology Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Artificial Intelligence in Pathology Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Artificial Intelligence in Pathology Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. AP-HP partners with Aiforia for advancing AI in prostate cancer diagnostics
  • 16.3.2. Quest diagnostics partners with PathAI to propel AI-driven cancer diagnosis
  • 16.3.3. Roche and PathAI collaborate to enhance AI-driven digital pathology for precision medicine
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. aetherAI
• 2. Aiforia Technologies Oyj
• 3. Akoya Biosciences, Inc.
• 4. Deep Bio, Inc.
• 5. Evident Corporation
• 6. F. Hoffmann-La Roche Ltd.
• 7. Ibex Medical Analytics Ltd.
• 8. Indica Labs, Inc.
• 9. Inspirata, Inc.
• 10. LUMEA, Inc.
• 11. MindPeak GmbH
• 12. Nucleai Inc.
• 13. OptraSCAN Inc.
• 14. Paige.AI, Inc.
• 15. PathAI, Inc.
• 16. Proscia Inc.
• 17. Techcyte, Inc.
• 18. Tempus Labs, Inc.
• 19. Tribun Health
• 20. Visikol, Inc. by CELLINK
• 21. Visiopharm A/S